Cipla Ltd. Share Price

Overview

Cipla Ltd. share price is currently ₹1,346.44, down by - ₹0.16 (0.01%) from its previous closing price of ₹1,346.60. The share price has declined -7.22% over the past month and declined -12.23% over the past year. The stock's 52-week low and high are ₹1,146.55 and ₹1,652.66, respectively. Cipla Ltd. has a market capitalisation of ₹ 1,10,000.00 Cr. The share price was last updated on 11 Sep 2026, 03:56 PM IST.

Cipla Ltd.
Cipla Ltd.
CIPLA
 0.00
- 0.16
0.01%
Healthcare
 0.00(%)1D

Updated: 11 Sep 2026, 03:56:35 pm IST

Market Data

Open Price

 1,353.87

Prev. Close

 1,346.60
 1,327.79

Day Low

 1,353.87

Day High

 1,146.55

52 Week Low

 1,652.66

52 Week High

HealthcarePharmaceuticals & Drugs
CategoryLarge Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

32.27

Sector PE

44.30

PB Ratio

3.16

Sector PB

5.94

EPS

41.73

Dividend Yield

1.06

Today's Volume

1.759 M

5 Day Avg. Volume

969.612 K

PEG Ratio

-1.22

Market Cap.

₹ 1,10,000.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 650% at ₹13/Share
05-Jun-202605-Jun-2026
DividendsSpecial Dividend of 150% at ₹3/Share
27-Jun-202527-Jun-2025
DividendsFinal Dividend of 650% at ₹13/Share
27-Jun-202527-Jun-2025

Mutual Fund Ownership

Mutual Fund Holder
Jul 26
Shares held
Aug 26
Shares held
HDFC Flexi Cap Fund - Growth1.99 Cr
1.99 Cr
no change
Parag Parikh Flexi Cap Fund - Regular Plan - Growth1.44 Cr
1.44 Cr
no change
SBI Nifty 50 ETF1.09 Cr
1.09 Cr
(0.53%)
ICICI Prudential Value Fund - Growth55.49 Lac
55.49 Lac
no change
SBI ELSS Tax Saver Fund - Regular Plan - IDCW47.57 Lac
47.57 Lac
no change

About Cipla Ltd. 👋

Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.

Expert Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Nikita (SEBI RA)

Nikita (SEBI RA)

13 Sep • 4:17 PM · SEBI-Registered Analyst

“Why Confirmation Improves Trade Quality”

A price level may look attractive, but entering immediately does not always provide a high-quality trade. Confirmation helps traders understand whether buyers or sellers are actually responding around an important area. This can reduce the chances of acting on a level that has not yet shown meaningful market participation. Confirmation can come through price action, breakout strength, rejection candles, volume or a change in market structure. The goal is not to predict every move, but to wait for evidence that supports the original trading idea. However, confirmation should not become an excuse to enter too late. Traders still need to consider the entry location, stop-loss distance and potential reward before taking the trade. Learning: Good confirmation adds confidence to a setup, but it should always be combined with proper risk management.

CIPLA

See More
CA Sumit Mangla

CA Sumit Mangla

11 Sep • 5:15 PM · SEBI-Registered Analyst

Glenmark Launches Ryaltris in Brazil for Rhinitis

GLENMARK
has expanded its global respiratory innovation footprint with the launch of Ryaltris in Brazil. The introduction marks the entry of the company’s differentiated dual-action therapy for allergic rhinitis into the Brazilian market. Ryaltris combines an antihistamine and a corticosteroid in a single nasal spray, offering convenient symptom relief for patients. The launch strengthens Glenmark’s presence in emerging markets and builds on the product’s existing approvals across multiple countries. This move supports the company’s strategy to grow its innovative respiratory portfolio and enhance access to advanced treatments for allergic rhinitis in Latin America. The Brazil launch is expected to contribute to Glenmark’s international specialty business expansion. **Top stocks in the pharmaceuticals industry:** Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Cipla.

See More
CA Sumit Mangla

CA Sumit Mangla

11 Sep • 9:57 AM · SEBI-Registered Analyst

Govt Plans Central Licensing for Sterile Drug Makers

The government plans to bring all sterile drug products under a central licensing system to tighten oversight following quality lapses. Around 240 injection samples were found not of standard quality in FY26, prompting the move to shift licensing from state authorities to the Central License Approving Authority. The proposal aims to replace the fragmented state-level system with uniform approval and inspection standards nationwide. It would require amendments to the Drugs Rules, 1945, and is intended to strengthen confidence in the quality of injectables and other sterile medicines manufactured for domestic and export markets. Higher compliance requirements are expected to raise the regulatory bar for sterile drug makers, particularly smaller units. The initiative forms part of broader efforts to improve manufacturing standards and address quality concerns in the pharmaceutical sector. **Top stocks in the pharmaceuticals industry:** Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and

CIPLA
.

See More
Nikita (SEBI RA)

Nikita (SEBI RA)

10 Sep • 1:03 PM · SEBI-Registered Analyst

“Why Patience Improves Trade Selection” ..

The market is continuously moving, but that does not mean every movement deserves a trading position. One of the most important skills in trading is knowing when the conditions are incomplete and waiting for the setup to develop. Impatient traders may enter because price is moving quickly, because they have recently missed an opportunity, or because they feel the need to remain active. These decisions can result in late entries, poor locations and unnecessary exposure. A patient trader waits for the conditions defined by the trading plan. This may include a specific market structure, a key price zone, confirmation, a clear invalidation point and an acceptable risk-to-reward relationship. If those conditions are not present, remaining out of the market is a valid decision. Patience does not mean avoiding action. It means reserving action for situations where the planned conditions are actually present. Learning: Selective participation can be more valuable than constant market activity.

CIPLA

See More
Ankush

Ankush

9 Sep • 8:56 AM · SEBI-Registered Analyst

Cipla Expands Oncology Portfolio with Key ADC Deal

CIPLA
Cipla is in focus after entering into an exclusive licensing and supply agreement with Sino Biopharmaceutical’s subsidiary CTTQ for TQB2102, a HER2-targeted bispecific antibody-drug conjugate (ADC). The deal gives Cipla rights to develop and commercialise the therapy in India, South Africa and five other emerging markets. TQB2102 is currently being evaluated for HER2-expressing cancers, including HER2-low advanced breast cancer. Cipla will handle local clinical development, regulatory activities and commercialisation, while CTTQ will continue manufacturing and supplying the drug. Separately, Cipla’s US subsidiary has partnered with China’s Qilu Pharmaceutical to license a biosimilar version of Merck’s Keytruda for the US market. The partnership strengthens Cipla’s strategy to expand its presence in complex biologics and oncology products. The latest deals could improve Cipla’s long-term product pipeline and strengthen its position in high-growth oncology markets. However, investors will continue to monitor regulatory developments, US business performance and the company’s ability to successfully commercialise these new products.

See More
Lovelesh Sharma

Lovelesh Sharma

9 Sep • 8:27 AM · SEBI-Registered Analyst

Cipla Weakens as Momentum Slips Below Trend Support

CIPLA
remains one of the stronger quality franchises within Indian pharma, with a diversified presence across domestic formulations, respiratory therapies and international markets. The broader pharmaceutical space continues to benefit from defensive earnings characteristics, chronic therapy growth and recurring demand, but stock-specific momentum can still diverge sharply from the sector theme. Technically, Cipla has slipped into a weaker phase after failing to sustain the rebound toward the ₹1,470–1,480 zone. Price is now near ₹1,384 and has moved below both the 20-day average around ₹1,423 and the 50-day average near ₹1,437. The shorter average has also started rolling lower, while price is forming a sequence of lower highs from the recent peak, showing that momentum has shifted back toward sellers. The ₹1,360–1,380 area becomes the immediate support zone, and a sustained break below it can reopen downside risk toward the ₹1,320–1,340 region. On the upside, the first sign of improvement would be a reclaim of ₹1,420, but a stronger trend recovery would need price back above ₹1,440–1,450. For now, the business remains resilient, but the chart is asking for patience.

See More

News & Events

Frequently Asked Questions

What is the share price of Cipla Ltd.?

What is the market cap of Cipla Ltd.?

Should I buy Cipla Ltd. stock now?

What is the 52 week high and low of Cipla Ltd.?

Is the Cipla Ltd. stock good to buy?

Is Cipla Ltd. a good buy for the long term?

Is Cipla Ltd. overvalued or undervalued?

What is the PE and PB ratio of Cipla Ltd.?

Start Now